<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097694</url>
  </required_header>
  <id_info>
    <org_study_id>2010P000170</org_study_id>
    <secondary_id>U01HL102225</secondary_id>
    <nct_id>NCT01097694</nct_id>
  </id_info>
  <brief_title>Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)</brief_title>
  <acronym>KIA</acronym>
  <official_title>A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether a new investigational drug (Imatinib) may help
      improve asthma in people whose symptoms are not well controlled with high dose inhaled
      corticosteroid treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe asthmatics remain poorly controlled despite high doses of standard asthma therapy or
      even daily doses of systemic corticosteroids or their equivalent. They account for a large
      proportion of the morbidity and mortality associated with asthma. Features that seem to
      characterize many patients with this disorder include persistent inflammation, symptoms, and
      airway hyperresponsiveness in the face of corticosteroid therapy. Mast cells are powerful,
      long-lived tissue dwelling effector cells that are resistant to corticosteroid effects and
      have been implicated in the pathobiology of asthma. Mast cells in the airway smooth muscle
      have been found to be the major distinguishing difference between asthmatic and non-asthmatic
      eosinophil airway disease; and putative circulating mast cell progenitors are increased 5
      fold in asthma. Stem cell factor (SCF) is critical to mast cell homeostasis and upregulation
      and has pleiotropic effects on mast cells and eosinophils . SCF levels are elevated in
      relation to asthma severity and SCF antibodies block hyperresponsiveness and inflammation and
      remodeling in murine asthma models. Imatinib, a specific tyrosine kinase inhibitor, inhibits
      cKit (Kit), the receptor for SCF on mast cells. Imatinib at doses equivalent to, or below,
      doses safely used in humans, also mimics or exceeds anti-SCF effects in the murine asthma
      model. Therefore we would like to know Does imatinib, an inhibitor of Kit, ameliorate severe
      asthma, in association with effects on lung mast cell phenotype and/or function?

      Specific Aims of the study are:

      Specific Aim 1: To investigate whether, in patients with persistent airway responsiveness and
      poor asthma control despite intensive asthma therapy, 24 weeks of imatinib therapy results in
      a reduction in airway responsiveness and in secondary indicators of asthma control, airway
      inflammation, and structural changes in the airways.

      Patients will be treated with imatinib in a randomized, double-blind, placebo controlled
      trial. Assessments will include methacholine and AMP reactivity, airway function, symptoms,
      airway wall thickness by CT scan, analysis of induced sputum, non-invasive markers of airway
      inflammation, and bronchoscopy including endobronchial biopsy and bronchoalveolar lavage -
      all before and at the end of therapy.

      Specific Aim 2: To investigate whether, in patients with persistent airway responsiveness and
      poor asthma control despite intensive asthma therapy, 24 weeks of imatinib therapy results in
      changes in airway mast cell population and/or phenotype.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at Month 3 and 6 Versus Baseline</measure>
    <time_frame>Over 6 months from beginning of treatment</time_frame>
    <description>Our primary outcome was change in airway hyperresponsiveness, as assessed by PC20, from baseline to 3 and/or 6 months of therapy in imatinib treated participants as compared with controls. Change in PC20 was assessed using log2-transformed ratios of PC20 at month 3 and /or month 6 vs PC20 at baseline. Our null hypothesis was that the mean of this ratio will be 0 after log2-transformed. We used a linear mixed-effects model for a repeated-measures analysis to compare the primary outcome between the two groups.
PC20 is determined by the provocation concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Total Tryptase</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in serum total tryptase after 24 weeks of imatinib vs placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar Lavage (BAL) Fluid Tryptase Level</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in BAL fluid tryptase levels after 24 weeks of imatinib vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Post-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) %</measure>
    <time_frame>6 months after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Asthma Exacerbations</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of asthma exacerbations experienced from randomization to study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 in Liters</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in FEV1 in treatment group compared to placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1%</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in FEV1% of predicted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Flow Measurement</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in patient-reported morning peak flow measurement (L/s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening Peak Flow</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in patient-reported evening peak flow measurement (L/s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Exhaled Nitric Oxide (FeNO)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in Fractional Exhaled Nitric Oxide Measurement (ppb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in patient-reported ACQ score The six-item Asthma Control Questionnaire (ACQ-6) is a scale from 0 to 6 with a lower value denoting an improvement in asthma control. The minimal important difference is 0.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life Questionnaire (AQLQ)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in patient-reported Asthma Quality of Life Questionnaire (AQLQ) score The asthma quality of life questionnaire (AQLQ) is a 32-item scale with a range from 1-7 with a higher value denoting improvement. The minimal important difference is 0.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Utility Index (ASUI)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in patient reported ASUI score The asthma symptom utility index (ASUI) is a 10-item weighted scale with a range from 0.2 to 1 with a higher value indicating improvement. The minimal important difference is 0.09.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAL Neutrophil %</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in BAL neutrophil percentage from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAL Eosinophil %</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in BAL eosinophil percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar Lavage (BAL) PGD2</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in bronchoalveolar lavage (BAL) PGD2 levels from baseline at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endobronchial Biopsy Total Tryptase-positive Mast Cells</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in endobronchial biopsy total tryptase-positive mast cells from baseline at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endobronchial Biopsy Smooth Muscle Tryptase-positive Mast Cells</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in the biopsy smooth muscle tryptase-positive mast cells from baseline at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Eosinophils</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in blood eosinophil count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway Wall Thickness</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in airway wall thickness as assessed by computerized tomography (CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway Wall Area</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in airway wall area as assessed by computerized tomography (CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar Lavage Histamine</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in bronchoalveolar lavage histamine levels from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Prostaglandin D2</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in urinary Prostaglandin D2 levels from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar Lavage Cysteinyl Leukotrienes</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in bronchoalveolar lavage cysteinyl leukotrienes levels from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Leukotriene E4</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Change in urinary leukotriene E4 levels from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sputum Supernatant Differential, Supernatant Tryptase and IL-13</measure>
    <time_frame>baseline to 24 weeks</time_frame>
    <description>Change in sputum eosinophil and neutrophil percentage. Change in sputum supernatant tryptase as measured by ELISA. Change in sputum IL-13 level as measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Mediators in Exhaled Breath Condensate</measure>
    <time_frame>baseline to week 24</time_frame>
    <description>Assessment of change in eicosanoids in the exhaled breath condensate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Self-Reported Asthma Symptom Free Days</measure>
    <time_frame>baseline to week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Imatinib mesylate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group on active imatinib treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group on Placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate</intervention_name>
    <description>Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
    <arm_group_label>Imatinib mesylate</arm_group_label>
    <other_name>Gleevec, Zoleta, Glivec, Ziatir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18-65 years of age, diagnosed with asthma for at least 1 year;

          2. Refractory asthma, defined as reporting that their asthma has not been completely
             controlled in the past 3 months despite continuous treatment with high-dose inhaled
             corticosteroids (ICS) and an additional controller medication, with or without
             continuous oral corticosteroids (OCS)

        Exclusion Criteria:

          1. Current smoking or smoking history of greater than 10 pack-years

          2. Any other significant respiratory or cardiac disease, or the presence of clinically
             important comorbidities, including uncontrolled diabetes, uncontrolled coronary artery
             disease

          3. If subject cannot undergo bronchoscopy procedure due to safety reasons

          4. Previous treatment with Imatinib

          5. A history of acute heart failure or chronic left sided heart failure

          6. Uncontrolled systemic arterial hypertension

          7. History of major bleeding or intracranial hemorrhage

          8. History of immunodeficiency diseases, including HIV

          9. Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer

         10. History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years, regardless of whether
             there is evidence of local recurrence or metastases.

         11. Diagnosis of Hepatitis B or C.

         12. History of alcohol abuse within 6 months of screening.

         13. History of illicit drug abuse within 6 months of screening.

         14. Regular use of anticoagulants (eg: Warfarin Sodium, Coumadin), amiodarone,
             carbamazepine, Cyclosporine, Rifampicin, or reverse transcriptase inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Israel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Womens Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joshua Boyce, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Womens Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Al-Muhsen SZ, Shablovsky G, Olivenstein R, Mazer B, Hamid Q. The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy. 2004 Jun;34(6):911-6.</citation>
    <PMID>15196279</PMID>
  </reference>
  <reference>
    <citation>Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med. 1992 Jan 1;175(1):237-44.</citation>
    <PMID>1370529</PMID>
  </reference>
  <reference>
    <citation>Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002 May 30;346(22):1699-705.</citation>
    <PMID>12037149</PMID>
  </reference>
  <reference>
    <citation>Campbell E, Hogaboam C, Lincoln P, Lukacs NW. Stem cell factor-induced airway hyperreactivity in allergic and normal mice. Am J Pathol. 1999 Apr;154(4):1259-65.</citation>
    <PMID>10233863</PMID>
  </reference>
  <reference>
    <citation>Carroll NG, Mutavdzic S, James AL. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax. 2002 Aug;57(8):677-82.</citation>
    <PMID>12149526</PMID>
  </reference>
  <reference>
    <citation>Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1062-71. Epub 2007 Sep 13.</citation>
    <PMID>17872493</PMID>
  </reference>
  <reference>
    <citation>Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000 Dec;162(6):2341-51. Review.</citation>
    <PMID>11112161</PMID>
  </reference>
  <reference>
    <citation>Lukacs NW, Kunkel SL, Strieter RM, Evanoff HL, Kunkel RG, Key ML, Taub DD. The role of stem cell factor (c-kit ligand) and inflammatory cytokines in pulmonary mast cell activation. Blood. 1996 Mar 15;87(6):2262-8.</citation>
    <PMID>8630386</PMID>
  </reference>
  <reference>
    <citation>Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.</citation>
    <PMID>19264687</PMID>
  </reference>
  <reference>
    <citation>Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol. 2006 Mar 8;533(1-3):327-40. Epub 2006 Feb 17. Review.</citation>
    <PMID>16483568</PMID>
  </reference>
  <reference>
    <citation>Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA. Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med. 1997 Jul 21;186(2):313-23.</citation>
    <PMID>9221761</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <results_first_submitted>April 4, 2017</results_first_submitted>
  <results_first_submitted_qc>May 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Elliot Israel, MD</investigator_full_name>
    <investigator_title>Director of the Asthma Research Center</investigator_title>
  </responsible_party>
  <keyword>cKIT inhibition in Asthma</keyword>
  <keyword>Efficacy of Imatinib in severe resistent asthma.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from November 2010 until December 2014 in seven academic medical centers.</recruitment_details>
      <pre_assignment_details>Following enrollment, 176 subjects entered a run-in period in which several inclusion criteria had to be met prior to randomization, including ACQ requirements and methacholine sensitivity, as well as safety and compliance requirements. 114 subjects who did not meet these inclusion criteria were not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Imatinib Mesylate</title>
          <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Group on Placebo treatment
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>severe asthmatics ages 18-65</population>
      <group_list>
        <group group_id="B1">
          <title>Imatinib Mesylate</title>
          <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Group on Placebo treatment
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="10.2"/>
                    <measurement group_id="B2" value="37.7" spread="11.8"/>
                    <measurement group_id="B3" value="40.1" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at Month 3 and 6 Versus Baseline</title>
        <description>Our primary outcome was change in airway hyperresponsiveness, as assessed by PC20, from baseline to 3 and/or 6 months of therapy in imatinib treated participants as compared with controls. Change in PC20 was assessed using log2-transformed ratios of PC20 at month 3 and /or month 6 vs PC20 at baseline. Our null hypothesis was that the mean of this ratio will be 0 after log2-transformed. We used a linear mixed-effects model for a repeated-measures analysis to compare the primary outcome between the two groups.
PC20 is determined by the provocation concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1).</description>
        <time_frame>Over 6 months from beginning of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at Month 3 and 6 Versus Baseline</title>
          <description>Our primary outcome was change in airway hyperresponsiveness, as assessed by PC20, from baseline to 3 and/or 6 months of therapy in imatinib treated participants as compared with controls. Change in PC20 was assessed using log2-transformed ratios of PC20 at month 3 and /or month 6 vs PC20 at baseline. Our null hypothesis was that the mean of this ratio will be 0 after log2-transformed. We used a linear mixed-effects model for a repeated-measures analysis to compare the primary outcome between the two groups.
PC20 is determined by the provocation concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1).</description>
          <units>Log2 Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.52"/>
                    <measurement group_id="O2" value="1.07" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Our null hypothesis was that the mean of this ratio will be 0 after log2-transformed.
The target enrollment was 60 assuming 10% drop-out for 54 completions which gave us 80% power to detect a doubling-dose change in PC20.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Total Tryptase</title>
        <description>Change in serum total tryptase after 24 weeks of imatinib vs placebo treatment</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Tryptase</title>
          <description>Change in serum total tryptase after 24 weeks of imatinib vs placebo treatment</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="2.32"/>
                    <measurement group_id="O2" value="-0.56" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchoalveolar Lavage (BAL) Fluid Tryptase Level</title>
        <description>Change in BAL fluid tryptase levels after 24 weeks of imatinib vs. placebo</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL) Fluid Tryptase Level</title>
          <description>Change in BAL fluid tryptase levels after 24 weeks of imatinib vs. placebo</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="2.35"/>
                    <measurement group_id="O2" value="0.43" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Maximum Post-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) %</title>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum Post-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) %</title>
          <units>% of predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.2"/>
                    <measurement group_id="O2" value="-0.08" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Asthma Exacerbations</title>
        <description>Number of asthma exacerbations experienced from randomization to study completion.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Asthma Exacerbations</title>
          <description>Number of asthma exacerbations experienced from randomization to study completion.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Poisson regression model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 in Liters</title>
        <description>Change in FEV1 in treatment group compared to placebo group</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 in Liters</title>
          <description>Change in FEV1 in treatment group compared to placebo group</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" lower_limit="0.036" upper_limit="0.056"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For FEV1 we used a linear mixed-effects model to assess the between-group difference in the change from baseline over weeks 8-24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for baseline values</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1%</title>
        <description>Change in FEV1% of predicted</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1%</title>
          <description>Change in FEV1% of predicted</description>
          <units>% of predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="8.86"/>
                    <measurement group_id="O2" value="0.78" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For FEV1% we used a linear mixed-effects model to assess the between-group difference in the change from baseline over weeks 8-24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Flow Measurement</title>
        <description>Change in patient-reported morning peak flow measurement (L/s)</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Flow Measurement</title>
          <description>Change in patient-reported morning peak flow measurement (L/s)</description>
          <units>L/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="46.1"/>
                    <measurement group_id="O2" value="-6.4" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Peak Flow</title>
        <description>Change in patient-reported evening peak flow measurement (L/s)</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Evening Peak Flow</title>
          <description>Change in patient-reported evening peak flow measurement (L/s)</description>
          <units>L/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="53.6"/>
                    <measurement group_id="O2" value="-8.2" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Exhaled Nitric Oxide (FeNO)</title>
        <description>Change in Fractional Exhaled Nitric Oxide Measurement (ppb)</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Exhaled Nitric Oxide (FeNO)</title>
          <description>Change in Fractional Exhaled Nitric Oxide Measurement (ppb)</description>
          <units>parts per billion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.89" spread="33.0"/>
                    <measurement group_id="O2" value="-5.92" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire (ACQ)</title>
        <description>Change in patient-reported ACQ score The six-item Asthma Control Questionnaire (ACQ-6) is a scale from 0 to 6 with a lower value denoting an improvement in asthma control. The minimal important difference is 0.5.</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (ACQ)</title>
          <description>Change in patient-reported ACQ score The six-item Asthma Control Questionnaire (ACQ-6) is a scale from 0 to 6 with a lower value denoting an improvement in asthma control. The minimal important difference is 0.5.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.96"/>
                    <measurement group_id="O2" value="-0.49" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Quality of Life Questionnaire (AQLQ)</title>
        <description>Change in patient-reported Asthma Quality of Life Questionnaire (AQLQ) score The asthma quality of life questionnaire (AQLQ) is a 32-item scale with a range from 1-7 with a higher value denoting improvement. The minimal important difference is 0.5.</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ)</title>
          <description>Change in patient-reported Asthma Quality of Life Questionnaire (AQLQ) score The asthma quality of life questionnaire (AQLQ) is a 32-item scale with a range from 1-7 with a higher value denoting improvement. The minimal important difference is 0.5.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="1.0"/>
                    <measurement group_id="O2" value="0.25" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Utility Index (ASUI)</title>
        <description>Change in patient reported ASUI score The asthma symptom utility index (ASUI) is a 10-item weighted scale with a range from 0.2 to 1 with a higher value indicating improvement. The minimal important difference is 0.09.</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Utility Index (ASUI)</title>
          <description>Change in patient reported ASUI score The asthma symptom utility index (ASUI) is a 10-item weighted scale with a range from 0.2 to 1 with a higher value indicating improvement. The minimal important difference is 0.09.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.20"/>
                    <measurement group_id="O2" value="0.05" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAL Neutrophil %</title>
        <description>Change in BAL neutrophil percentage from baseline</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>BAL Neutrophil %</title>
          <description>Change in BAL neutrophil percentage from baseline</description>
          <units>% neutrophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="5.6"/>
                    <measurement group_id="O2" value="-0.4" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAL Eosinophil %</title>
        <description>Change in BAL eosinophil percentage</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>BAL Eosinophil %</title>
          <description>Change in BAL eosinophil percentage</description>
          <units>% eosinophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="8.8"/>
                    <measurement group_id="O2" value="-2.63" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchoalveolar Lavage (BAL) PGD2</title>
        <description>Change in bronchoalveolar lavage (BAL) PGD2 levels from baseline at 6 months</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL) PGD2</title>
          <description>Change in bronchoalveolar lavage (BAL) PGD2 levels from baseline at 6 months</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="57.2"/>
                    <measurement group_id="O2" value="-4.2" spread="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endobronchial Biopsy Total Tryptase-positive Mast Cells</title>
        <description>Change in endobronchial biopsy total tryptase-positive mast cells from baseline at 6 months</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endobronchial Biopsy Total Tryptase-positive Mast Cells</title>
          <description>Change in endobronchial biopsy total tryptase-positive mast cells from baseline at 6 months</description>
          <units>mast cells per mm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.2" spread="96.5"/>
                    <measurement group_id="O2" value="-32.3" spread="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endobronchial Biopsy Smooth Muscle Tryptase-positive Mast Cells</title>
        <description>Change in the biopsy smooth muscle tryptase-positive mast cells from baseline at 6 months</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endobronchial Biopsy Smooth Muscle Tryptase-positive Mast Cells</title>
          <description>Change in the biopsy smooth muscle tryptase-positive mast cells from baseline at 6 months</description>
          <units>mast cells per mm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-102.7" spread="167.9"/>
                    <measurement group_id="O2" value="-79.2" spread="157.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Eosinophils</title>
        <description>Change in blood eosinophil count</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Eosinophils</title>
          <description>Change in blood eosinophil count</description>
          <units>eosinophils per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="50.6"/>
                    <measurement group_id="O2" value="-2.6" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Airway Wall Thickness</title>
        <description>Change in airway wall thickness as assessed by computerized tomography (CT)</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Wall Thickness</title>
          <description>Change in airway wall thickness as assessed by computerized tomography (CT)</description>
          <units>% of airway</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0040" spread="0.03"/>
                    <measurement group_id="O2" value="-0.0027" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Airway Wall Area</title>
        <description>Change in airway wall area as assessed by computerized tomography (CT)</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Wall Area</title>
          <description>Change in airway wall area as assessed by computerized tomography (CT)</description>
          <units>% of area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0002" spread="0.02"/>
                    <measurement group_id="O2" value="0.0002" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchoalveolar Lavage Histamine</title>
        <description>Change in bronchoalveolar lavage histamine levels from baseline</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage Histamine</title>
          <description>Change in bronchoalveolar lavage histamine levels from baseline</description>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="6.3"/>
                    <measurement group_id="O2" value="-1.1" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Prostaglandin D2</title>
        <description>Change in urinary Prostaglandin D2 levels from baseline</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Prostaglandin D2</title>
          <description>Change in urinary Prostaglandin D2 levels from baseline</description>
          <units>ng/mg Creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="1.5"/>
                    <measurement group_id="O2" value="0.39" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchoalveolar Lavage Cysteinyl Leukotrienes</title>
        <description>Change in bronchoalveolar lavage cysteinyl leukotrienes levels from baseline</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage Cysteinyl Leukotrienes</title>
          <description>Change in bronchoalveolar lavage cysteinyl leukotrienes levels from baseline</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="37.3"/>
                    <measurement group_id="O2" value="6.5" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Leukotriene E4</title>
        <description>Change in urinary leukotriene E4 levels from baseline</description>
        <time_frame>6 months after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Leukotriene E4</title>
          <description>Change in urinary leukotriene E4 levels from baseline</description>
          <units>ng/mg Creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.65"/>
                    <measurement group_id="O2" value="0.01" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sputum Supernatant Differential, Supernatant Tryptase and IL-13</title>
        <description>Change in sputum eosinophil and neutrophil percentage. Change in sputum supernatant tryptase as measured by ELISA. Change in sputum IL-13 level as measured by ELISA.</description>
        <time_frame>baseline to 24 weeks</time_frame>
        <population>Sputum sample slide preparation quality was poor and samples meeting quality control were insufficient for analysis of sputum differential.
Insufficient study funds prevented assessment of sputum tryptase. IL-13 was below the detection limit of assay in sputum supernatant.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sputum Supernatant Differential, Supernatant Tryptase and IL-13</title>
          <description>Change in sputum eosinophil and neutrophil percentage. Change in sputum supernatant tryptase as measured by ELISA. Change in sputum IL-13 level as measured by ELISA.</description>
          <population>Sputum sample slide preparation quality was poor and samples meeting quality control were insufficient for analysis of sputum differential.
Insufficient study funds prevented assessment of sputum tryptase. IL-13 was below the detection limit of assay in sputum supernatant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Mediators in Exhaled Breath Condensate</title>
        <description>Assessment of change in eicosanoids in the exhaled breath condensate</description>
        <time_frame>baseline to week 24</time_frame>
        <population>The exhaled breath condensate was not processed for inflammatory mediators.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Mediators in Exhaled Breath Condensate</title>
          <description>Assessment of change in eicosanoids in the exhaled breath condensate</description>
          <population>The exhaled breath condensate was not processed for inflammatory mediators.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Self-Reported Asthma Symptom Free Days</title>
        <time_frame>baseline to week 24</time_frame>
        <population>Self-reported asthma symptom free days were not entered into the study database.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group on Placebo treatment
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Self-Reported Asthma Symptom Free Days</title>
          <population>Self-reported asthma symptom free days were not entered into the study database.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from randomization to study drug vs. placebo up to 24 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Imatinib Mesylate</title>
          <description>Group on active imatinib treatment
Imatinib mesylate: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Group on Placebo treatment
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute URI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg Cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ankle Dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abnormal LFTs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Back/Shoulder Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elliot Israel, MD</name_or_title>
      <organization>Brigham and Women's Hopsital</organization>
      <phone>617-732-8110</phone>
      <email>eisrael@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

